Ignacio A. Casarini
Mar Del Plata, B, Argentina
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study.
Journal: JCO oncology practice
Published: June 03, 2026
A plain language review of results from the LAURA study: osimertinib after chemoradiotherapy for patients with EGFR-mutated non-small cell lung cancer that cannot be removed by surgery.
Journal: Future oncology (London, England)
Published: April 27, 2026
Corrigendum to "Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial": [Ann Oncol 36 (2025) 775-785].
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 08, 2026
Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 05, 2026
Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 10, 2025
Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: February 21, 2025
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.
Journal: The New England journal of medicine
Published: June 03, 2024
Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 10, 2023
Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress.
Journal: Clinical lung cancer
Published: September 02, 2020
Showing 1-9 of 9
Last Updated: 09/26/2026